CLC number: R54
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 2012-06-27
Cited: 2
Clicked: 5468
Jian-an Wang. Progress and challenges in the cardiovascular field[J]. Journal of Zhejiang University Science B, 2012, 13(8): 587-588.
@article{title="Progress and challenges in the cardiovascular field",
author="Jian-an Wang",
journal="Journal of Zhejiang University Science B",
volume="13",
number="8",
pages="587-588",
year="2012",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1201010"
}
%0 Journal Article
%T Progress and challenges in the cardiovascular field
%A Jian-an Wang
%J Journal of Zhejiang University SCIENCE B
%V 13
%N 8
%P 587-588
%@ 1673-1581
%D 2012
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1201010
TY - JOUR
T1 - Progress and challenges in the cardiovascular field
A1 - Jian-an Wang
J0 - Journal of Zhejiang University Science B
VL - 13
IS - 8
SP - 587
EP - 588
%@ 1673-1581
Y1 - 2012
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1201010
Abstract: Despite great achievements in their treatment and prevention in the past few decades, cardiovascular diseases remain the leading cause of human mortality and morbidity all around the world. As estimated by the world health organization (WHO) in 2008, over 17 million people die from cardiovascular diseases every year. It is reported that in China we have around 23 million cardiovascular disease patients, along with a significant disease burden (Zhao and Liu, 2012). Business corporations and non-profit health organizations, physicians and biomedical scientists are making great progress in preventing and treating cardiovascular diseases. Due to the globalization of information technology, we are able to access the latest progress in the biomedical field, or look back to the achievements of past decades. However, there are still some ways to go before our guidelines or expert consensus can be used to benefit patients (Huo, 2010). Moreover, numerous new diagnostic techniques and therapeutic methods (including drugs, devices, biomedical materials, and surgical operations) are created every year, making it more and more difficult for physicians to make the optimal choice for patients (Wang, 2010). Therefore, it is of vital importance to introduce, interpret, discuss and summarize information on cardiovascular diseases.
[1]Gao, C., Wang, Y., 2012. Global impact of RNA splicing on transcriptome remodeling in the heart. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 13(8):603-608.
[2]Gao, F., Hu, X.Y., Xie, X.J., Xu, Q.Y., Wang, Y.P., Liu, X.B., Xiang, M.X., Sun, Y., Wang, J.A., 2010. Heat shock protein 90 protects rat mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis via the PI3K/Akt and ERK1/2 pathways. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 11(8):608-617.
[3]Ge, J.B., 2012. Current status of percutaneous coronary intervention of chronic total occlusion. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 13(8):589-602.
[4]Hu, X.Y., Wang, W.X., Yu, M.J., Liu, X.B., Wu, R.R., Gao, F., Huang, X., Cao, J., Xie, X.J., Wang, J.A., 2011. Tongxinluo promotes mesenchymal stem cell tube formation in vitro. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 12(8):644-651.
[5]Huo, Y., 2010. Current status and development of percutaneous coronary intervention in China. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 11(8):631-633.
[6]Jiang, J., Sun, Y., Xiang, M.X., Dong, L., Liu, X.B., Hu, X.Y., Feng, Y., Wang, J.A., 2012. Complex coronary lesions and rotational atherectomy: one hospital’s experience. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 13(8):645-651.
[7]Kim, W.T., Ahn, S.G., Lee, J.W., Sung, J.K., Lee, S.H., Yoon, J., 2010. Successful recanalization of chronic total occlusion of the superior mesenteric artery by transradial approach. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 11(8):627-630.
[8]Li, P., Gai, L.Y., Yang, X., Sun, Z.J., Jin, Q.H., 2010. Computed tomography angiography-guided percutaneous coronary intervention in chronic total occlusion. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 11(8):568-574.
[9]Lip, G.Y., 2011. Atrial fibrillation in 2011: stroke prevention in AF. Nat. Rev. Cardiol., 9(2):71-73.
[10]Lip, G.Y., Tse, H.F., Lane, D.A., 2012. Atrial fibrillation. Lancet, 379(9816):648-661.
[11]Liu, X.B., Chen, H., Chen, H.Q., Zhu, M.F., Hu, X.Y., Wang, Y.P., Jiang, Z., Xu, Y.C., Xiang, M.X., Wang, J.A., 2012. Angiopoietin-1 preconditioning enhances survival and functional recovery of mesenchymal stem cell transplantation. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 13(8):616-623.
[12]Nanni, L., Romualdi, C., Maseri, A., Lanfranchi, G., 2006. Differential gene expression profiling in genetic and multifactorial cardiovascular diseases. J. Mol. Cell. Cardiol., 41(6):934-948.
[13]Wang, J.A., 2010. Advances in cardiovascular disease: how far is the summit? J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 11(8):547.
[14]Zeller, T., Blankenberg, S., Diemert, P., 2012. Genomewide association studies in cardiovascular disease―an update 2011. Clin. Chem., 58(1):92-103.
[15]Zhang, S., 2012. Clinical considerations of anticoagulation therapy for patients with atrial fibrillation. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 13(8):609-615.
[16]Zhao, D., Liu, J., 2012. Cardiovascular disease in China: increasing burden ahead for prevention. Chin. J. Cardiol., 40(3):177-178 (in Chinese).
Open peer comments: Debate/Discuss/Question/Opinion
<1>